Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
7 Cheap Biotech Stocks With Major Upside Potential
06:00am, Tuesday, 09'th Jul 2024
Intuitively, the case for biotechnology-related investments comes across rather obviously: the concept of healthcare should be a permanent one. And because of this permanence, the expected market valu
Insider Buying Heats Up at Fracker, Aircraft and Boat Makers, and More
09:15am, Sunday, 02'nd Jun 2024
With the earnings-reporting season having all but concluded, the windows for making insider purchases are generally open.
Exelixis to Present at the William Blair 44th Annual Growth Stock Conference
04:05pm, Tuesday, 28'th May 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the William Blair 44th Annual Growth Stock Conference on
Exelixis (EXEL) Settles Cabometyx Patent Litigation With Cipla
12:21pm, Tuesday, 21'st May 2024
Exelixis (EXEL) resolves two patent litigations and grants Cipla a license to market generic versions of Cabometyx in the United States beginning January 2031.
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
08:00am, Monday, 20'th May 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectivel
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
01:25pm, Sunday, 12'th May 2024
Novo Nordisk and Exelixis are favorites of billionaire Jim Simons' hedge fund. Novo Nordisk has a deep lineup and pipeline and expertise in diabetes and obesity.
Just Say No to Drugs: 3 Pharma Stocks to Avoid
10:30am, Wednesday, 08'th May 2024
From its stellar performance in 2021 to deflating in 2022, the biotech sector continued its stagnation into 2023, highlighting some pharma stocks to avoid. Year-to-date, the S&P Biotechnology Select I
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
04:05pm, Tuesday, 07'th May 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following investor conferences i
Exelixis (EXEL) International Revenue Performance Explored
01:11pm, Monday, 06'th May 2024
Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
10:16am, Wednesday, 01'st May 2024
Exelixis (EXEL) misses on earnings and sales in the first quarter. Its shares are trading down in response to the results.
Exelixis, Inc. (EXEL) Q1 2024 Earnings Call Transcript
09:27pm, Tuesday, 30'th Apr 2024
Exelixis, Inc. (NASDAQ:EXEL ) Q1 2024 Earnings Conference Call April 30, 2024 5:00 PM ET Company Participants Varant Shirvanian - Director of Investor Relations Michael Morrissey - President and Chief
Exelixis (EXEL) Reports Q1 Earnings: What Key Metrics Have to Say
07:31pm, Tuesday, 30'th Apr 2024
Although the revenue and EPS for Exelixis (EXEL) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
04:05pm, Tuesday, 30'th Apr 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2024, provided an update on progress toward achieving key corporate objectives
The Top 3 Biotech Stocks to Buy in April 2024
07:00am, Saturday, 27'th Apr 2024
Biotech stocks are notorious for being some of the most volatile and unpredictable on the market. With clinical trials and FDA approvals creating potential leaps or falls in what seems like an instant
EXEL vs. REGN: Which Stock Is the Better Value Option?
12:45pm, Thursday, 25'th Apr 2024
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Regeneron (REGN). But which of these two stocks is more attractive to value inve
